Brian Lam
About
Brian Lam is a scholar working on Epidemiology, Hepatology and Infectious Diseases.
According to data from OpenAlex, Brian Lam has authored 43 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Epidemiology, 24 papers in Hepatology and 8 papers in Infectious Diseases. Recurrent topics in Brian Lam's work include Liver Disease Diagnosis and Treatment (31 papers), Liver Disease and Transplantation (11 papers) and Hepatitis C virus research (11 papers). Brian Lam is often cited by papers focused on Liver Disease Diagnosis and Treatment (31 papers), Liver Disease and Transplantation (11 papers) and Hepatitis C virus research (11 papers). Brian Lam collaborates with scholars based in United States, Australia and Malaysia. Brian Lam's co-authors include Zobair M. Younossi, Maria Stepanova, Manirath Srishord, Youssef Younossi, Francesco Negro, Linda Henry, Sharon Hunt, Fatema Nader, Thomas L. Jeffers and Andrei Racila and has published in prestigious journals such as Gastroenterology, PLoS ONE and Diabetes.
In The Last Decade
Brian Lam
41 papers receiving 1.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Brian Lam United States | 18 | 1.2k | 753 | 414 | 189 | 165 | 43 | 1.4k | ||
| Chapy Venkatesan United States | 16 | 1.1k 0.9× | 807 1.1× | 259 0.6× | 157 0.8× | 82 0.5× | 24 | 1.4k | ||
| Jian-Gao Fan China | 4 | 915 0.8× | 324 0.4× | 383 0.9× | 200 1.1× | 204 1.2× | 5 | 1.2k | ||
| E Fassio Argentina | 21 | 1.2k 1.0× | 883 1.2× | 333 0.8× | 144 0.8× | 81 0.5× | 45 | 1.5k | ||
| Helma Pinchemel Cotrim Brazil | 22 | 967 0.8× | 488 0.6× | 437 1.1× | 216 1.1× | 78 0.5× | 81 | 1.4k | ||
| Rajiv Baijal India | 14 | 680 0.6× | 300 0.4× | 312 0.8× | 137 0.7× | 136 0.8× | 29 | 1.0k | ||
| Arka De India | 15 | 699 0.6× | 461 0.6× | 202 0.5× | 103 0.5× | 83 0.5× | 110 | 1.0k | ||
| Parijat Gupte India | 10 | 707 0.6× | 273 0.4× | 366 0.9× | 143 0.8× | 143 0.9× | 16 | 981 | ||
| Thomas G. Cotter United States | 18 | 1.2k 1.1× | 672 0.9× | 349 0.8× | 224 1.2× | 57 0.3× | 55 | 1.7k | ||
| Bradford Waters United States | 13 | 585 0.5× | 444 0.6× | 221 0.5× | 73 0.4× | 88 0.5× | 33 | 924 | ||
| Cynthia Behling United States | 17 | 1.7k 1.4× | 714 0.9× | 819 2.0× | 115 0.6× | 135 0.8× | 27 | 2.2k |
Countries citing papers authored by Brian Lam
Since
Specialization
Citations
This map shows the geographic impact of Brian Lam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Lam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Lam more than expected).
Fields of papers citing papers by Brian Lam
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Brian Lam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Lam. The network helps show where Brian Lam may publish in the future.
Co-authorship network of co-authors of Brian Lam
This figure shows the co-authorship network connecting the top 25 collaborators of Brian Lam. A scholar is included among the top collaborators of Brian Lam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Lam. Brian Lam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mandarino, Francesco Vito, Sunil Gupta, Brian Lam, et al.. (2025). Margin thermal ablation eliminates size as a risk factor for recurrence after piecemeal endoscopic mucosal resection of large non-pedunculated colorectal polyps. Gut. 74(5). 752–760.
2.
Younossi, Zobair M., Sean Felix, Brian Lam, et al.. (2025). Serum Bile Acid Elevation is an Independently Associated With Pruritus in Patients With At-risk Metabolic Dysfunction-associated Steatotic Liver Disease. Journal of Clinical and Experimental Hepatology. 15(4). 102549–102549.
3.
Schmutz, Beat, et al.. (2025). Effect of age, sex, height, ethnicity, and femoral bowing on the anatomical fitting of the LCP distal femur plate. Archives of Orthopaedic and Trauma Surgery. 145(1). 472–472.
4.
Mandarino, Francesco Vito, Brian Lam, Sunil Gupta, et al.. (2025). Impact of margin thermal ablation after cold-forceps avulsion with snare-tip soft coagulation for nonlifting large nonpedunculated colorectal polyps. Endoscopy. 57(7). 730–739.
5.
Younossi, Zobair M., Michael Estep, Sean Felix, et al.. (2024). Type 2 diabetes and the minor allele of PNPLA3 consistently identify high-risk metabolic dysfunction associated steatotic liver disease. Diabetes Research and Clinical Practice. 219. 111960–111960.
6.
Younossi, Zobair M., Maria Stepanova, Sean Felix, et al.. (2023). The combination of the enhanced liver fibrosis and FIB‐4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 57(12). 1417–1422.
7.
Lam, Brian, et al.. (2023). How long is too long: A retrospective study evaluating the impact of the duration of noninvasive oxygenation support strategies (high flow nasal cannula & BiPAP) on mortality in invasive mechanically ventilated patients with COVID-19. PLoS ONE. 18(2). e0281859–e0281859.
8.
Lam, Brian, Maria Stepanova, Chapy Venkatesan, et al.. (2022). Outcomes of hospitalized patients with COVID-19 during the course of the pandemic in a fully integrated health system. PLoS ONE. 17(2). e0263417–e0263417.
9.
Younossi, Zobair M., Yusuf Yılmaz, Mohamed El‐Kassas, et al.. (2022). The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry. Hepatology Communications. 6(10). 2860–2866.
10.
Younossi, Zobair M., Naim Alkhouri, Fasiha Kanwal, et al.. (2022). A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 57(3). 304–312.
11.
Stepanova, Maria, Brian Lam, Elena Younossi, et al.. (2022). The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19. BMC Infectious Diseases. 22(1). 702–702.
12.
Younossi, Zobair M., Maria Stepanova, Brian Lam, et al.. (2021). Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection. Hepatology Communications. 6(11). 3062–3072.
13.
Alqahtani, Saleh A., Pegah Golabi, James M. Paik, et al.. (2021). Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Obesity Surgery. 31(5). 2002–2010.
14.
Younossi, Zobair M., Sean Felix, Thomas L. Jeffers, et al.. (2021). Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography. Clinical Gastroenterology and Hepatology. 20(5). e1149–e1156.
15.
Stepanova, Maria, Brian Lam, Andrei Racila, et al.. (2021). Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience. Clinical Infectious Diseases. 74(6). 1063–1069.
16.
Karrar, Azza, Dinan Abdelatif, Ali Moosvi, et al.. (2020). Major Histocompatibility Complex Class I‐Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver Disease. Hepatology Communications. 5(1). 63–73.
17.
Younossi, Zobair M., Kathleen E. Corey, Naim Alkhouri, et al.. (2020). Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices. Alimentary Pharmacology & Therapeutics. 52(3). 513–526.
18.
Sayıner, Mehmet, Brian Lam, Pegah Golabi, & Zobair M. Younossi. (2018). Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therapeutic Advances in Gastroenterology. 11. 3972000372–3972000372.
19.
Younossi, Zobair M., Maria Stepanova, Linda Henry, et al.. (2017). A disease‐specific quality of life instrument for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis: CLDQ ‐NAFLD . Liver International. 37(8). 1209–1218.
20.
Younossi, Zobair M., Maria Stepanova, Fatema Nader, Brian Lam, & Sharon Hunt. (2015). The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon‐ and ribavirin‐free regimens: a study of health‐related quality of life. Alimentary Pharmacology & Therapeutics. 42(3). 286–295.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Chapy Venkatesan Breakdown of academic impact, for papers by Jian-Gao Fan Breakdown of academic impact, for papers by E Fassio Breakdown of academic impact, for papers by Helma Pinchemel Cotrim Breakdown of academic impact, for papers by Rajiv Baijal Breakdown of academic impact, for papers by Arka De Breakdown of academic impact, for papers by Parijat Gupte Breakdown of academic impact, for papers by Thomas G. Cotter Breakdown of academic impact, for papers by Bradford Waters Breakdown of academic impact, for papers by Cynthia Behling